Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies
In the treatment of advanced NSCLC in China, pembrolizumab, particularly when considering the drug donation program, offers better survival outcomes and becomes cost-effective. This highlights the importance of such programs in making high-cost treatments accessible in real-world clinical settings.
Authors
- Weiting Liang (ORCID: https://orcid.org/0000-0002-9573-5709)
- Ning Wan (ORCID: https://orcid.org/0000-0001-8876-626X)
- Zhuojia Chen (ORCID: https://orcid.org/0000-0003-0343-3795)
- Ning Yang (ORCID: https://orcid.org/0000-0001-5772-3320)
- Dandan Yang
- Bing Wang (ORCID: https://orcid.org/0000-0001-9646-0404)
- Yajuan Lv (ORCID: https://orcid.org/0000-0001-8570-5154)
- Tao Liu (ORCID: https://orcid.org/0000-0001-6244-7316)
- Yang Chen (ORCID: https://orcid.org/0000-0002-9838-0843)
- Guo Ya
- ZiJian He
- Wenfeng Fang (ORCID: https://orcid.org/0000-0002-6440-8246)
- Jin Yuan (ORCID: https://orcid.org/0000-0001-6807-1815)
- Liqing Lu
- Yongyuan Chen
- WeiBin Xiao
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Sun Yat-sen University (CN)
- Jinan University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- The First People's Hospital of Shunde (CN)
- General Hospital of Guangzhou Military Command (CN)
- Southern Command Hospital (IN)
- Sun Yat-sen University Cancer Center (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1007/s00432-025-06242-6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Basic and Applied Basic Research Foundation of Guangdong Province